{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:43:34Z","timestamp":1794865414294,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004913","name":"Universit\u00e0 degli Studi di Palermo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004913","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-025-05049-w","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T01:48:47Z","timestamp":1739843327000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Use of semaglutide in a 54-year-old patient with cocaine abuse and weight loss: a case report"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2464-0531","authenticated-orcid":false,"given":"V. M.","family":"Romeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"issue":"2","key":"5049_CR1","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1210\/en.2011-1443","volume":"153","author":"AL Alhadeff","year":"2012","unstructured":"Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus tractus solitarius project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology. 2012;153(2):647\u201358.","journal-title":"Endocrinology"},{"issue":"9","key":"5049_CR2","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/dom.12932","volume":"19","author":"J Blundell","year":"2017","unstructured":"Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242\u201351.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"5049_CR3","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1176\/appi.ajp.162.8.1452","volume":"162","author":"KM Carroll","year":"2005","unstructured":"Carroll KM, Onken LS. Behavioral therapies for drug abuse. Am J Psychiatry. 2005;162(8):1452\u201360.","journal-title":"Am J Psychiatry"},{"key":"5049_CR4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.appet.2007.05.007","volume":"50","author":"C Davis","year":"2008","unstructured":"Davis C, Patte K, Curtis C, Reid C. Immediate pleasures and future consequences. A neuropsychological study of binge eating and obesity. Appetite. 2008;50:224\u20139.","journal-title":"Appetite"},{"issue":"7","key":"5049_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"M Davies","year":"2015","unstructured":"Davies M, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687\u201399. https:\/\/doi.org\/10.1001\/jama.2015.9676.","journal-title":"JAMA"},{"issue":"1","key":"5049_CR6","first-page":"46","volume":"23","author":"M Davies","year":"2021","unstructured":"Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of semaglutide on glycaemic control in patients with type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Obes Metab. 2021;23(1):46\u201357.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"5049_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.physbeh.2012.03.019","volume":"106","author":"SL Dickson","year":"2012","unstructured":"Dickson SL, Egecioglu E, Landgren S, et al. The role of the central GLP-1 system in reward and motivation. Physiol Behav. 2012;106(3):312\u20139. https:\/\/doi.org\/10.1016\/j.physbeh.2012.03.019.","journal-title":"Physiol Behav"},{"issue":"9548","key":"5049_CR8","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696\u2013705. https:\/\/doi.org\/10.1016\/S0140-6736(06)69705-5.","journal-title":"Lancet"},{"issue":"5","key":"5049_CR9","first-page":"785","volume":"18","author":"E Egecioglu","year":"2013","unstructured":"Egecioglu E, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue exendin-4 attenuates the reinforcing properties of alcohol in rodents. Addict Biol. 2013;18(5):785\u201396.","journal-title":"Addict Biol"},{"issue":"4","key":"5049_CR10","first-page":"203","volume":"71","author":"AN Fabricatore","year":"2011","unstructured":"Fabricatore AN, Wadden TA, Higginbotham AJ, et al. Intentional weight loss and changes in symptoms of depression: a systematic review and meta-analysis. J Psychosom Res. 2011;71(4):203\u201310.","journal-title":"J Psychosom Res"},{"issue":"2","key":"5049_CR11","first-page":"297","volume":"25","author":"AN Gearhardt","year":"2011","unstructured":"Gearhardt AN, Corbin WR, Brownell KD. Development of the Yale Food Addiction Scale version 2.0. Psychol Addict Behav. 2011;25(2):297\u2013306.","journal-title":"Psychol Addict Behav"},{"key":"5049_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.pbb.2019.06.014","volume":"183","author":"K Guillem","year":"2019","unstructured":"Guillem K, Ahmed SH, Peoples LL, Rossignol E. The promise of GLP-1 receptor agonists for the treatment of cocaine and opioid addictions. Pharmacol Biochem Behav. 2019;183:72\u20139. https:\/\/doi.org\/10.1016\/j.pbb.2019.06.014.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"5049_CR13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50\u20135.","journal-title":"Br J Med Psychol"},{"issue":"1","key":"5049_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5049_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fnins.2015.00092","volume":"9","author":"KM Heppner","year":"2015","unstructured":"Heppner KM, Perez-Tilve D. GLP-1 based therapeutics: simultaneously combating T2DM and obesity. Front Neurosci. 2015;9:92.","journal-title":"Front Neurosci"},{"issue":"4","key":"5049_CR16","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409\u201339.","journal-title":"Physiol Rev"},{"issue":"7","key":"5049_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40273-014-0243-x","volume":"33","author":"A Hruby","year":"2015","unstructured":"Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2015;33(7):673\u201389.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"5049_CR18","first-page":"1175","volume":"14","author":"L Karila","year":"2011","unstructured":"Karila L, Gorelick D, Weinstein A, et al. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol. 2011;14(9):1175\u201389.","journal-title":"Int J Neuropsychopharmacol"},{"key":"5049_CR19","first-page":"123","volume":"8","author":"PJ Kenny","year":"2014","unstructured":"Kenny PJ. GLP-1 receptors in addiction and reward. Front Neurosci. 2014;8:123.","journal-title":"Front Neurosci"},{"issue":"1","key":"5049_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/npp.2009.110","volume":"35","author":"GF Koob","year":"2010","unstructured":"Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217\u201338.","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"5049_CR21","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1001\/jamasurg.2016.2317","volume":"151","author":"ML Maciejewski","year":"2016","unstructured":"Maciejewski ML, Arterburn DE, Van Scoyoc L. Bariatric surgery and long-term durability of weight loss. JAMA Surg. 2016;151(11):1046\u201355.","journal-title":"JAMA Surg"},{"issue":"4","key":"5049_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"12","key":"5049_CR23","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728\u201342. https:\/\/doi.org\/10.1038\/nrendo.2012.140.","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"5049_CR24","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/obr.12589","volume":"18","author":"R Nogueiras","year":"2017","unstructured":"Nogueiras R, Romero-Pic\u00f3 A, L\u00f3pez M. The role of GLP-1 in the regulation of energy balance and its potential in the treatment of obesity. Obes Rev. 2017;18(11):1116\u201327. https:\/\/doi.org\/10.1111\/obr.12589.","journal-title":"Obes Rev"},{"issue":"1","key":"5049_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/026988119801200103","volume":"12","author":"CP O'Brien","year":"1998","unstructured":"O\u2019Brien CP, Childress AR, Ehrman R, Robbins SJ. Conditioning factors in drug abuse: can they explain compulsion? J Psychopharmacol. 1998;12(1):15\u201322.","journal-title":"J Psychopharmacol"},{"issue":"8","key":"5049_CR26","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1176\/appi.ajp.162.8.1423","volume":"162","author":"CP O'Brien","year":"2005","unstructured":"O\u2019Brien CP. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry. 2005;162(8):1423\u201331.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"5049_CR27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.physbeh.2011.04.063","volume":"104","author":"SL Parylak","year":"2011","unstructured":"Parylak SL, Koob GF, Zorrilla EP. The dark side of food addiction. Physiol Behav. 2011;104(1):149\u201356.","journal-title":"Physiol Behav"},{"issue":"1","key":"5049_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"5","key":"5049_CR29","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2337\/dc16-2309","volume":"40","author":"JC Rodriguez","year":"2017","unstructured":"Rodriguez JC, Campbell JE. GLP-1 receptor agonists: efficacy and safety in clinical trials. Diabetes Care. 2017;40(5):583\u201390. https:\/\/doi.org\/10.2337\/dc16-2309.","journal-title":"Diabetes Care"},{"issue":"1","key":"5049_CR30","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1038\/ijo.2010.184","volume":"34","author":"M Rosenbaum","year":"2010","unstructured":"Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes. 2010;34(1):S47\u201355.","journal-title":"Int J Obes"},{"issue":"11","key":"5049_CR31","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/nrn2026","volume":"7","author":"HD Schmidt","year":"2006","unstructured":"Schmidt HD, McFarland K, Pierce RC. Neuroplasticity in addiction: lessons from cocaine. Nat Rev Neurosci. 2006;7(11):841\u201350. https:\/\/doi.org\/10.1038\/nrn2026.","journal-title":"Nat Rev Neurosci"},{"key":"5049_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.brainres.2012.01.032","volume":"1471","author":"KP Skibicka","year":"2012","unstructured":"Skibicka KP, Shirazi RH, Rabasa-Papio C, Dickson SL. GLP-1 and its role in reward: from food to alcohol. Brain Res. 2012;1471:169\u201377. https:\/\/doi.org\/10.1016\/j.brainres.2012.01.032.","journal-title":"Brain Res"},{"issue":"1","key":"5049_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/adb.12181","volume":"20","author":"G Sorensen","year":"2015","unstructured":"Sorensen G, Medhus S, Gronli J. Glucagon-like peptide-1 receptor agonists: a potential novel treatment for alcohol use disorder. Addict Biol. 2015;20(1):23\u201332. https:\/\/doi.org\/10.1111\/adb.12181.","journal-title":"Addict Biol"},{"issue":"4","key":"5049_CR34","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/dom.13631","volume":"21","author":"G Sorensen","year":"2019","unstructured":"Sorensen G, Bentsen MA, Linneberg A, Thomsen M. The potential of GLP-1 receptor agonists for treating alcohol use disorder: a review. Diabetes Obes Metab. 2019;21(4):749\u201359. https:\/\/doi.org\/10.1111\/dom.13631.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"5049_CR35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.drugalcdep.2005.11.022","volume":"83","author":"BD Sussner","year":"2006","unstructured":"Sussner BD, Smelson DA, Rodrigues S, et al. The validity and reliability of a brief measure of cocaine craving. Drug Alcohol Depend. 2006;83(3):233\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"5049_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0376-8716(93)90042-O","volume":"34","author":"ST Tiffany","year":"1993","unstructured":"Tiffany ST, Singleton E, Haertzen CA, Henningfield JE. The development of a cocaine craving questionnaire. Drug Alcohol Depend. 1993;34(1):19\u201328.","journal-title":"Drug Alcohol Depend"},{"key":"5049_CR37","first-page":"53","volume":"10","author":"D Vallof","year":"2016","unstructured":"Vallof D, Engel JA. Role of central GLP-1 in psychostimulant and opioid use disorder. Front Neurosci. 2016;10:53.","journal-title":"Front Neurosci"},{"issue":"4","key":"5049_CR38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/026988119901300406","volume":"13","author":"ND Volkow","year":"1999","unstructured":"Volkow ND, Fowler JS, Wang GJ. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J Psychopharmacol. 1999;13(4):337\u201345.","journal-title":"J Psychopharmacol"},{"issue":"1507","key":"5049_CR39","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1098\/rstb.2008.0107","volume":"363","author":"ND Volkow","year":"2008","unstructured":"Volkow ND, Wang GJ, Fowler JS, Telang F. Overlapping neuronal circuits in addiction and obesity: evidence of systems pathology. Philos Trans Royal Soc B Biol Sci. 2008;363(1507):3191\u2013200. https:\/\/doi.org\/10.1098\/rstb.2008.0107.","journal-title":"Philos Trans Royal Soc B Biol Sci"},{"issue":"10","key":"5049_CR40","first-page":"758","volume":"3","author":"ND Volkow","year":"2016","unstructured":"Volkow ND, Koob GF. Brain disease model of addiction: why is it so controversial? Lancet Psychiatry. 2016;3(10):758\u201360.","journal-title":"Lancet Psychiatry"},{"key":"5049_CR41","volume-title":"Case study research: design and methods","author":"RK Yin","year":"2014","unstructured":"Yin RK. Case study research: design and methods. 5th ed. Thousand Oaks: Sage Publications; 2014.","edition":"5"},{"key":"5049_CR42","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S0140-6736(00)03643-6","volume":"357","author":"GJ Wang","year":"2001","unstructured":"Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet. 2001;357:354\u20137.","journal-title":"Lancet"},{"issue":"3\u20134","key":"5049_CR43","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00213-010-2086-5","volume":"213","author":"G Wegener","year":"2010","unstructured":"Wegener G, Volke V. Gene-environment interactions in the context of depression: synchronizing pathophysiology and treatment response. Psychopharmacology. 2010;213(3\u20134):573\u201385. https:\/\/doi.org\/10.1007\/s00213-010-2086-5.","journal-title":"Psychopharmacology"},{"issue":"11","key":"5049_CR44","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JP Wilding","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"key":"5049_CR45","unstructured":"World Health Organization. Obesity and overweight. 2021. https:\/\/iris.who.int\/bitstream\/handle\/10665\/43035\/9241592222_eng.pdf?sequence=1."}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-025-05049-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T01:48:55Z","timestamp":1739843335000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05049-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5049"],"URL":"https:\/\/doi.org\/10.1186\/s13256-025-05049-w","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I assure that all ethical standards required for this type of research have been met. No ethics committee approval was required. Patient consent for treatment was requested and obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"I declare that there are no competing financial or nonfinancial interests that could have influenced the outcomes of this research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}